EMA Authorised: Jeraygo (aprocitentan) — Idorsia Pharmaceuticals Deutschland GmbH

View source ↗

Summary

The EMA authorised Jeraygo (aprocitentan) for the treatment of hypertension. Idorsia Pharmaceuticals Deutschland GmbH is the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Jeraygo (aprocitentan)

Snippet

Status: Authorised. Therapeutic area: Hypertension. MAH: Idorsia Pharmaceuticals Deutschland GmbH. Decision date: 29/01/2026